Daunorubicin 20mg Injection
Daunorubicin 20mg Injection is an anticancer drug which belongs to the Anthracycline group.
It is an antibiotic derived from fungus Streptomyces coeruleorubidus that has cytotoxic effects on multiple stages of the growing cell.
It is a prescription only drug and requires a healthcare professional to administer & monitor.
Mechanism of action:It acts by binding to DNA through intercalation leading to inhibition of DNA and RNAsynthesis.It laso acts by inhibiting the action of topoisomerase II; by generating free radicals through reductive process and by binding to cellular membranes to alter transport across the membrane. All these actions result in the death of the cancer cell.
It is available as DaunoXome and Cerubidine in the International market and Daunotec in Indian market.
Tell the doctor about any pre existing medical condition, ongoing medications and any type of allergy.
1. What is Daunotec Injection?
Daunotec is an anticancer medicine containing daunorubicin, an anthracycline chemotherapy medicine used under specialist medical supervision for certain types of cancer.
2. What is Daunotec used for?
Daunotec (Daunorubicin) is primarily used as part of chemotherapy treatment for certain blood cancers, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), according to the prescribed treatment protocol.
3. How does Daunotec work?
Daunotec works by interfering with DNA replication and other processes required for cancer-cell growth. This can prevent cancer cells from multiplying and contributes to its anticancer effect.
4. How is Daunotec Injection administered?
Daunotec is administered intravenously by a qualified healthcare professional. The dosage and treatment schedule are determined by the treating oncologist based on the patient’s condition and chemotherapy regimen.
5. What are the possible side effects of Daunotec?
Possible side effects may include nausea, vomiting, diarrhea, hair loss, mouth sores, fatigue, fever, infections, and reduced blood cell counts. Patients should report severe or persistent symptoms to their healthcare professional.